Compare Gilead Sciences, Inc. (GILD) vs Medtronic PLC (MDT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Medtronic PLC — how do they compare? Gilead Sciences, Inc. trades at $135.34 (market cap $168.35B), while Medtronic PLC trades at $90.25 (market cap $116.07B). The key difference: Gilead Sciences, Inc. is the larger of the two by market cap, and Medtronic PLC pays the higher dividend (3.18%). Which is the better fit depends on your goals.
| GILD | MDT | |
|---|---|---|
Market Cap | $168.35B | $116.07B |
Sector | Health | Health |
52-Week High | $155.80 | $105.35 |
52-Week Low | $110.56 | $73.75 |
Enterprise Value | $191.42B | $134.82B |
Dividend Yield | 2.42% | 3.18% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Medtronic PLC
One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →
